Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.45 |
| ▸ | IDH2 | P48735 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NPR3 | P17342 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686884 | 0.89 | IDH1 (0.45) | IDH1IDH2CNR1PRCPMAPK1 | |
| SCHEMBL19686885 | 0.86 | IDH1 (0.38) | IDH1IDH2MAPK8ROCK2SYK | |
| SCHEMBL19686612 | 0.80 | KCNN2 (0.39) | IDH1SYKKDM1AMAPK1 | |
| SCHEMBL21143813 | 0.78 | IDH1 (0.41) | IDH1IDH2CNR1MAPK1MAPK3 | |
| SCHEMBL19686879 | 0.77 | S1PR2 (0.46) | SYK | |
| SCHEMBL31127253 | 0.75 | IDH1 (0.41) | IDH1IDH2CNR1SYKMAPK1 | |
| SCHEMBL21166186 | 0.75 | IDH1 (0.41) | IDH1IDH2CNR1SYKMAPK1 | |
| SCHEMBL21143642 | 0.74 | IDH1 (0.39) | IDH1IDH2CNR1PRCPMAPK8 | |
| SCHEMBL21143647 | 0.74 | IDH1 (0.45) | IDH1IDH2CNR1PRCPKDM1A | |
| SCHEMBL19686593 | 0.73 | KCNN2 (0.49) | IDH1MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885CNR1 770/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885CNR1 770/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885CNR1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.